Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Nov 2026 · 1 min read
In brief
In brief
This case report describes severe cytokine release syndrome occurring after PD-1 checkpoint inhibitor therapy in a young patient with alveolar soft part sarcoma. The presentation highlights an uncommon but serious immune-related adverse event associated with checkpoint blockade immunotherapy.
Written by the GCMD Library team from the article.
Cytokine release syndrome (CRS) is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy. Checkpoint blockade using anti-programmed cell death 1 (anti-PD-1) inhibitors is an approach to antitumor immune system stimulation. A 29-year-old female with alveolar soft part sarcoma developed severe CRS after treatment with anti-PD-1 thera…
Statements in this article
Cytokine release syndrome is a phenomenon of immune hyperactivation described in the setting of cellular and bispecific T-cell engaging immunotherapy.
Severe cytokine release syndrome can occur in patients receiving anti-PD-1 checkpoint blockade therapy.
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Article
In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
Joseph G. Pressey · Published Nov 2026
Article
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Joseph G. Pressey · Published May 2025
Article
Pediatric BRAF (V600E)-Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib
Joseph G. Pressey · Published Jan 2020
Article
Herpes simplex virus oncolytic therapy for pediatric malignancies
Joseph G. Pressey · Published Apr 2009
Article
Embryonal rhabdomyosarcoma with a novel t(2;6)(p23;p21.1).
Joseph G. Pressey · Published Nov 2026
Article
Comorbidity Burden in a Cohort of Adolescent and Young Adult Patients Diagnosed with Central Nervous System Tumors and Sarcomas.
Joseph G. Pressey · Published Nov 2026
Article
Current concepts on the surgical and medical management of osteosarcoma.
Joseph G. Pressey · Published Nov 2026
Article
Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.
Joseph G. Pressey · Published Nov 2026
Article
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Joseph G. Pressey · Published Nov 2026
Article
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.
Joseph G. Pressey · Published Nov 2026